Ghana

  • Coordonnées de contact
  • Informations sur l'organisation
  • Resources
  • Publications
  • Informations supplémentaires

Ghana Health Service Ethical Review Committee

Ghana Health Service

Research and Development Division

Chairperson
Dr John Gyapong (John.Gyapong@hru-ghs.org)

Nom de l'organisme administrateur ou la personne à contacter
Dr Hannah Frimpong (Hannah.Frimpong@hru-ghs.org)

Numéro de téléphone: 233 021 681109

Numéro de fax:

Adresse postale
Ghana Health Service Ethical Review Research and Development Division Ghana Health Service Adabraka Polyclinic Opposite Accra Psychiatric Hospital Cathedral Square Castle Road Accra

Adresse physique
Ghana Health Service Ethical Review Committee Research and Development Division P. O. Box MB 190 Accra. Ghana Health Service Ethical Review Committee Accra Ghana

Pays
Ghana

URL de l'institution
http://www.ghanahealthservice.org/division.php?dsion=Research and Development&dd=35

Informations sur l'organisation

Quelle est l'affiliation institutionnelle de votre organisation
Government

 

Level of operation

What is the level of operation
Institutional

 

Informations relatives à la soumission des protocoles

Quelle est la (les) langue(s) de fonctionnement de l'organisation
English

Si vous avez un calendrier, nous vous demandons de bien vouloir nous fournir les informations le concernant ici
The members of the committee meet every two months to review and take decisions on research protocols. In addition, a four member sub-committee is put in place during recess of the Committee, to carry out expedited reviews of protocols.

Si vous voulez que n'importe quelle autre information concernant le organisation apparaisse sur
Requirements for ethical approval: • Scientific Review approval • Overall Study design • Methodology • Sampling and Sample size i.e. selection processes/ inclusion and exclusion criteria • Procedures and arrangement for Referral Services/Basic level of follow up care and Medical support for Adverse Effects (if study is invasive/ clinical trial) • Arrangement for follow ups (if study is invasive/clinical trial) • Food and Drugs Boards approval letter Investigational Product • Material Transfer Agreement • Profile of Data Safety Monitoring Board (DSMB) and their charter of work • Ethical Considerations (risks & benefits) • Insurance Cover for participants • Budget • Sponsors • Investigational Brochure for investigations products • Collaborators CVs and Institutional letter

 

 

Cancel